Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TARA-002
Therapeutic Area: Rare Diseases and Disorders Product Name: TARA-002
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cowen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering September 21, 2020
Details:
Protara intends to use the net proceeds from the Offerings primarily for development activities associated with TARA-002 in non-muscle invasive bladder cancer, lymphatic malformations and potential exploration of additional indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RZL 012
Therapeutic Area: Rare Diseases and Disorders Product Name: RZL 012
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Fosun Pharmaceutical
Deal Size: $74.0 million Upfront Cash: $27.0 million
Deal Type: Licensing Agreement September 17, 2020
Details:
RZL-012 is an injectable drug product indicated for aesthetic treatment of adults having moderate to significant submental fullness. Under the terms of the agreement, Raziel Therapeutics will receive potential payments between now and marketing approval in the Territory.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Clemizole hydrochloride
Therapeutic Area: Rare Diseases and Disorders Product Name: EPX-100
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: GreenLight Clinical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
This Phase 2 study will confirm the efficacy and safety of EPX-100 with children suffering from Dravet Syndrome. The Company is now recruiting patients for this clinical study, collaborated with GreenLight Clinical.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TARA-002
Therapeutic Area: Rare Diseases and Disorders Product Name: TARA-002
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
FDA Confirmed Initial Comparability Between TARA-002 and OK-432; Final GMP Comparability Expected to be Completed in Mid-2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TARA-002
Therapeutic Area: Rare Diseases and Disorders Product Name: TARA-002
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
TARA-002 is an investigational cell-based therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for the treatment of LMs. LMs are rare, typically congenital, malformations of the lymphatic vasculature.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
